Literature DB >> 23199487

Relapse.

Nicholas J White1, Mallika Imwong.   

Abstract

Plasmodium vivax is a major cause of febrile illness in endemic areas of Asia, Central and South America, and the horn of Africa. P. vivax infections are characterized by relapses of malaria arising from persistent liver stages of the parasite (hypnozoites), which can be prevented currently only by 8-aminoquinoline anti-malarials. Tropical P. vivax infections relapse at approximately 3-week intervals if rapidly eliminated anti-malarials are given for treatment, whereas in temperate regions and parts of the sub-tropics, P. vivax infections are characterized by either a long incubation or a long-latency period between illness and relapse - in both cases approximating 8-10 months. The epidemiology of the different relapse phenotypes has not been defined adequately despite obvious relevance to malaria therapeutic assessment, control, and elimination. The number of sporozoites inoculated by the anopheline mosquito is an important determinant of both the timing and the number of relapses. The intervals between P. vivax relapses display a remarkable periodicity which has not been explained. Evidence is presented that the proportion of patients who have successive relapses is relatively constant and that the factor which activates hypnozoites and leads to regular interval relapse in vivax malaria is the systemic febrile illness itself. It is proposed that in endemic areas, a large proportion of the population harbours latent hypnozoites which can be activated by a systemic illness such as vivax or falciparum malaria. This explains the high rates of vivax following falciparum malaria, the high proportion of heterologous genotypes in relapses, the higher rates of relapse in people living in endemic areas compared with artificial infection studies, and, by facilitating recombination between different genotypes, contributes to P. vivax genetic diversity particularly in low transmission settings. Long-latency P. vivax phenotypes may be more widespread and more prevalent than currently thought. These observations have important implications for the assessment of radical treatment efficacy and for malaria control and elimination.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199487     DOI: 10.1016/B978-0-12-397900-1.00002-5

Source DB:  PubMed          Journal:  Adv Parasitol        ISSN: 0065-308X            Impact factor:   3.870


  78 in total

Review 1.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

2.  Challenges for Plasmodium vivax malaria elimination in the genomics era.

Authors:  Marcelo U Ferreira; Thaís Crippa de Oliveira
Journal:  Pathog Glob Health       Date:  2015-05       Impact factor: 2.894

3.  A 38-year-old man with fever and a history of malaria.

Authors:  Vanessa Redditt; Isaac Bogoch; Meb Rashid
Journal:  CMAJ       Date:  2018-09-10       Impact factor: 8.262

4.  Higher Complexity of Infection and Genetic Diversity of Plasmodium vivax Than Plasmodium falciparum Across All Malaria Transmission Zones of Papua New Guinea.

Authors:  Abebe A Fola; G L Abby Harrison; Mita Hapsari Hazairin; Céline Barnadas; Manuel W Hetzel; Jonah Iga; Peter M Siba; Ivo Mueller; Alyssa E Barry
Journal:  Am J Trop Med Hyg       Date:  2017-04-06       Impact factor: 2.345

5.  Malarial liver parasites awaken in culture.

Authors:  John W Barnwell; Mary R Galinski
Journal:  Nat Med       Date:  2014-03       Impact factor: 53.440

6.  High Efficacy of Primaquine Treatment for Plasmodium vivax in Western Thailand.

Authors:  Rhea J Longley; Piyarat Sripoorote; Pornpimol Chobson; Teerawat Saeseu; Chonlaphat Sukasem; Suparat Phuanukoonnon; Wang Nguitragool; Ivo Mueller; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2016-09-06       Impact factor: 2.345

7.  Development and validation of serological markers for detecting recent Plasmodium vivax infection.

Authors:  Rhea J Longley; Michael T White; Eizo Takashima; Jessica Brewster; Masayuki Morita; Matthias Harbers; Thomas Obadia; Leanne J Robinson; Fumie Matsuura; Zoe S J Liu; Connie S N Li-Wai-Suen; Wai-Hong Tham; Julie Healer; Christele Huon; Chetan E Chitnis; Wang Nguitragool; Wuelton Monteiro; Carla Proietti; Denise L Doolan; Andre M Siqueira; Xavier C Ding; Iveth J Gonzalez; James Kazura; Marcus Lacerda; Jetsumon Sattabongkot; Takafumi Tsuboi; Ivo Mueller
Journal:  Nat Med       Date:  2020-05-11       Impact factor: 53.440

Review 8.  The Biology of Plasmodium vivax.

Authors:  John H Adams; Ivo Mueller
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

9.  Detection of mixed-species infections of Plasmodium falciparum and Plasmodium vivax by nested PCR and rapid diagnostic tests in southeastern Iran.

Authors:  Reyhaneh Ehtesham; Asghar Fazaeli; Ahmad Raeisi; Hossein Keshavarz; Aliehsan Heidari
Journal:  Am J Trop Med Hyg       Date:  2015-05-11       Impact factor: 2.345

10.  Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.

Authors:  Yue Qiu; Yan Zhao; Fei Liu; Bo Ye; Zhenjun Zhao; Sataporn Thongpoon; Wanlapa Roobsoong; Jetsumon Sattabongkot; Liwang Cui; Qi Fan; Yaming Cao
Journal:  Vaccine       Date:  2020-02-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.